GRIT Biotechnology key facts
as of Oct 2026- Developer of immunotherapy intended to cure solid tumors.
- GRIT Biotechnology is valued at approximately $291.3M as of Oct 2026 (last reported valuation).
- It has raised $124.2M; the latest was Later Stage VC ($53.3M) in Oct 2025.
- Notable investors include GL Ventures, CICC Capital, B Capital Group, Green Pine Capital Partners, Qianhai FoF — 22 tracked in total.
- Status: Privately Held (backing).
GRIT Biotechnology's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 22 names
- ·Watch GRIT Biotechnology: the Monday email on marks, rounds and moves
GRIT Biotechnology funding rounds
No funding rounds for GRIT Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs GRIT Biotechnology
22+GRIT Biotechnology valuation
GRIT Biotechnology's last reported valuation was $291 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
GRIT Biotechnology investors
22 investors are on record for GRIT Biotechnology, including GL Ventures, CICC Capital, B Capital Group and Green Pine Capital Partners. By type, the record holds 5 venture capital firms and 2 private equity firms.
About GRIT Biotechnology
Developer of immunotherapy intended to cure solid tumors. The company develops and researches Tumor Infiltration Lymphocytes (TIL) immunotherapy for solid tumors, committing to improving the treatment of tumors.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 130
- Website
- grit-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.